CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Jun '19 Jun 30, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
Rental Revenue	0.01	-	-	1.58	2.92	2.71
Tenant Reimbursements	-	-	-	0.55	0.94	0.83
Total Revenue	0.01	-	-	2.14	3.86	3.54
Revenue Growth (YoY	-	-	-	-44.59%	8.96%	-
Property Expenses	0	-	-	0.68	1.37	1.27
Selling, General & Administrative	5.67	4.08	2.65	0.92	-	-
Depreciation & Amortization	-	-	-	0.95	2.11	2.45
Provision for Loan Losses	-	-	-	-0.01	-0.02	-0.03
Total Operating Expenses	5.68	4.08	2.65	2.56	3.5	3.76
Operating Income	-5.66	-4.08	-2.65	-0.42	0.36	-0.22
Interest Expense	-4.1	-2.96	-0.63	-0.75	-1.53	-1.53
Other Non-Operating Income	0	0.41	-0.49	-	0	-
EBT Excluding Unusual Items	-9.76	-6.63	-3.77	-1.17	-1.18	-1.74
Gain (Loss) on Sale of Assets	-0.04	-0.04	-	-	-	-
Other Unusual Items	-15.59	-15.59	-	-	-	-
Pretax Income	-25.4	-22.27	-3.77	-1.17	-1.18	-1.74
Earnings From Continuing Operations	-25.4	-22.27	-3.77	-1.17	-1.18	-1.74
Minority Interest in Earnings	0.42	-	-	0.04	0.18	0.26
Net Income	-24.98	-22.27	-3.77	-1.13	-1	-1.48
Preferred Dividends & Other Adjustments	2.2	0.43	-	-	-	-
Net Income to Common	-27.18	-22.7	-3.77	-1.13	-1	-1.48
Basic Shares Outstanding	363	3	2	-	-	-
Diluted Shares Outstanding	363	3	2	-	-	-
Shares Change (YoY)	555.00%	29.60%	-	-	-	-
EPS (Basic)	-0.07	-8.74	-1.88	-	-	-
EPS (Diluted)	-0.07	-8.74	-1.88	-	-	-
Operating Margin	-40446.79%	-	-	-19.77%	9.26%	-6.10%
Profit Margin	-194109.49%	-	-	-53.00%	-25.90%	-41.82%
EBITDA	-	-	-	-	2.46	2.24
EBITDA Margin	-	-	-	-	63.83%	63.18%
D&A For Ebitda	-	-	-	-	2.11	2.45
EBIT	-5.66	-4.08	-2.65	-0.42	0.36	-0.22
EBIT Margin	-	-	-	-19.77%	9.26%	-6.10%
Revenue as Reported	-	-	-	2.14	3.86	3.54

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.